Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience after 3 Years' Follow-up

Clinical Neuropharmacology

Volumn 38, Issue 4, 2015, Pages 132-134

  Todorova, Antoniya ^a   Samuel, Michael ^a   Brown, Richard G ^b,c   Chaudhuri, Kallol Ray ^a,c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Neuropsychology Unit   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

apomorphine infusion; impulse control disorders; Levodopa infusion; Parkinson disease

Indexed keywords

APOMORPHINE; LEVODOPA; ROTIGOTINE; ANTIPARKINSON AGENT;

ADULT; ARTICLE; BINGE EATING DISORDER; CLINICAL ARTICLE; COMPULSION; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMBLING; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; INTERNET ADDICTION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; AGED; COHORT ANALYSIS; COMPLICATION; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DRUG ADMINISTRATION ROUTE; MIDDLE AGED;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; COHORT STUDIES; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84938329303     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000091     Document Type: Article

References (16)

1. Weintraub D, Koester J, Potenza MN, Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67 (5): 589-595.
2. O'Sullivan SS, Evans AH, Lees AJ,. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009; 23 (2): 157-170.
3. 11C] raclopride PET study. Brain 2009; 132 (Pt 5): 1376-1385.
4. Evans AH, Pavese N, Lawrence AD, Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852-858.
5. Volkmann J, Albanese A, Antonini A, Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol 2013; 60 (11): 2701-2714.
6. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicentre study. Mov Disord 2008; 23 (8): 1130-1136.
7. Magennis B, Cashell A, O'Brien D, An audit of apomorphine in the management of complex idiopathic Parkinson's disease in Ireland. Mov Disord 2012; 27 (Suppl 1): S44.
8. Cilia R, Siri C, Canesi M, Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry 2014; 85 (3): 311-318.
9. Martinez-Martin P, Reddy P, Katzenschlager R, EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2015; 30: 510-516.
10. Martinez-Martin P, Reddy P, Antonini A, Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real-life study of non-motor effect. J Parkinsons Dis 2011; 1: 197-203.
11. Reddy P, Martinez-Martin P, Rizos A, Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol 2012; 35: 205-207.
12. Chaudhuri KR, Martinez-Martin P, Schapira A, International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest Study. Mov Disord 2006; 21: 916-923.
13. Weintraub D, Stewart S, Shea JA, Validation of a questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP). Mov Disord 2009; 24: 1461-1467.
14. Rizos A, Martinez-Martin P, Martin A, European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD. Mov Disord 2012; 27 (Suppl): 161.
15. Trenkwalder C, Kies B, Rudsinska M, Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomised, placebo-controlled study (RECOVER). Mov Disord 2011; 26 (1): 90-99.
16. Antonini A, Tolosa E, Mizuno Y, A reassessment of risk and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009; 8: 929-937.